• Purity

  >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to induce IFN-gamma secretion by NK‑92 human natural killer lymphoma cells. Brandt, C.S.     et al. (2009) J. Exp. Med.     206:1495. The ED    ₅₀ for this effect is 0.5-2.5 μg/mL.

• Source

  Human embryonic kidney cell, HEK293-derived

  Cynomolgus B7-H6 (Asp25-Ser262) Accession # XP_005578557	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Asp25

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  53 kDa

• SDS-PAGE

  70-81 kDa, reducing conditions

Background: B7-H6

B7-H6 is a 55 kDa glycosylated member of the B7 family of immune costimulatory proteins (1, 2). Mature B7-H6 consists of an extracellular domain (ECD) that with one Ig-like V domain and one Ig-like C1 domain, a transmembrane segment, and a cytoplasmic domain that contains one ITIM, one SH2, and one SH3 motif (3). Both of the Ig-like domains carry N-linked glycosylation (4). Within the ECD, cynomolgous B7-H6 shares 81%, 81%, 77% and 80% amino acid sequence identity with chimpanzee, orangutan, gibbon, and human B7-H6, respectively. Orthologs in mouse and rat have not been identified. The Ig-like V domain mediates 1:1 stoichiometric binding of B7-H6 to NKp30 expressed on NK cells (4, 5). It does not show binding to NKp44, NKp46, or NKG2D (3, 6). Ligation of NKp30 by B7-H6 induces NK cell activation and target cell cytolysis (3). B7-H6 is expressed on a wide range of hematopoietic, carcinoma, and melanoma tumor cells, which is consistent with the detection of NKp30 binding sites on many tumors (3, 7). B7-H6 is up-regulated on inflammatory monocytes and neutrophils, and a 30 kDa soluble fragment can be released by ADAM-10 or ADAM-17 mediated shedding (8, 9). The expression of B7-H6 on tumor cells correlates with cancer progression and patient's survival in human ovarian cancer (10).

• References:

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.

2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.

3. Brandt, C.S. et al. (2009) J. Exp. Med. 206:1495.

4. Li, Y. et al. (2011) J. Exp. Med. 208:703.

5. Joyce, M.G. et al. (2011) Proc. Natl. Acad. Sci. USA 108:6223.

6. Arnon, T.I. et al. (2006) Semin. Cancer Biol. 16:348.

7. Byrd, A. et al. (2007) PLoS ONE 2:e1339.

8. Matta, J. et al. (2013) Blood 122:394.

9. Schlecker, E. et al. (2014) Cancer Res. 74:3429.

10. Zhou, Y. et al. (2015) Int. J. Clin. Exp. Pathol. 8:9428.

• Long Name:

  B7 Homolog 6

• Entrez Gene IDs:

  374383 (Human); 102121659 (Cynomolgus Monkey)

• Alternate Names:

  B7 homolog 6; B7H6; B7-H6; DKFZp686I21167; DKFZp686O24166; NCR3LG1